Monoclonal antibody · Acts on West Nile virus envelope protein · developed by MacroGenics
MGAWN1 is a humanized monoclonal antibody directed against West Nile virus. It is studied in West Nile neuroinvasive disease, including encephalitis, meningitis and acute flaccid paralysis, as well as West Nile fever.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00927953 | Phase 2 | West Nile Neuroinvasive Disease | Terminated | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Flaccid ParalysisEncephalitisMeningitisWest Nile FeverWest Nile Neuroinvasive DiseaseWest Nile Virus Infection
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →